Antengene has announced that it will present posters featuring ATG-022 and ATG-037 at ESMO 2026, one of the major international meetings in cancer research and treatment. The update signals that both programs will be part of the company’s scientific presence at the event.
The announcement puts a spotlight on Antengene’s oncology pipeline, with ATG-022 and ATG-037 set to be discussed in poster format for researchers and industry attendees. Poster presentations are commonly used to share early or ongoing findings with the wider oncology community during large medical congresses.
Antengene, which is listed in Hong Kong, describes itself as a global biotech company with commercial-stage operations and a focus on developing innovative medicines. Its planned participation at ESMO 2026 reflects continued efforts to advance internal drug candidates and raise their profile in front of clinicians, scientists and potential partners.
While the company’s release highlights the upcoming presentations, the brief announcement does not detail the full data package in the trimmed text available. Even so, the ESMO appearance underscores Antengene’s intention to keep investors and the medical field updated on progress involving ATG-022 and ATG-037.
